The study investigated the impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on cardiovascular outcomes in individuals aged 45 or older with preexisting cardiovascular disease and overweight or obesity but without diabetes. In a double-blind trial, patients received either weekly subcutaneous semaglutide (2.4 mg) or a placebo. The primary cardiovascular endpoint (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred less frequently in the semaglutide group (6.5%) compared to the placebo group (8.0%). The hazard ratio was 0.80, indicating a significant reduction in cardiovascular events with semaglutide. However, adverse events leading to discontinuation were higher in the semaglutide group. In conclusion, semaglutide demonstrated superiority over placebo in reducing cardiovascular events in this population without diabetes.
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
Leave a Reply